文献速递慢性肾脏病

肥胖与代谢综合征对CKD患者心血管事件、肾衰竭进展及全因死亡的影响

How obesity and metabolic syndrome affect cardiovascular events, progression to kidney failure and all-cause mortality in chronic kidney disease.
PubMed 文献 · Nephrol Dial Transplant · 2024-01-01

结果显示,无MetS的肥胖患者心血管事件和进展至ESKD风险未增加,全因死亡风险显著降低,且肥胖削弱了代谢异常与心血管风险之间的关联。

要点

  • 无MetS的肥胖CKD患者心血管事件风险未增加(调整HR 1.02)。
  • 无MetS的肥胖CKD患者进展至ESKD风险未增加(调整HR 0.92)。
  • 无MetS的肥胖CKD患者全因死亡风险显著降低(调整HR 0.82)。

核心结论

  • 无MetS的肥胖不增加CKD患者心血管并发症或进展至ESKD的风险。
  • 肥胖对全因死亡风险的健康效应及其对代谢危害与心血管风险关联的削弱效应应在CKD患者中予以考虑。

研究设计与样本

  • 肥胖定义为体重指数≥25 kg/m2,MetS定义为存在3个或以上代谢风险因素。

主要发现

  • 心血管事件、进展至ESKD和全因死亡的累积事件率在无MetS的肥胖患者中最低(均P < .001)。
  • 多变量分析中,无MetS的肥胖(对比非肥胖)患者心血管事件风险未增加[调整HR 1.02(95%CI 0.94-1.11)],进展至ESKD风险未增加[0.92(0.77-1.09)]。
  • 无MetS的肥胖患者全因死亡风险显著降低[0.82(0.75-0.90)]。
  • 上述发现在无MetS的超重、肥胖和重度肥胖患者中一致观察到。
  • 肥胖和非肥胖患者中每增加一个代谢异常的HR均线性增加,但肥胖患者心血管事件HR增加的斜率显著更慢(交互作用P = .038)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity and metabolic syndrome (MetS) are prevalent among chronic kidney disease (CKD) patients. However, it is unclear whether obesity without MetS is associated with a higher risk of adverse clinical outcomes in CKD patients. METHODS: We searched the National Health Insurance Service database of Korea for patients who underwent national health screenings in 2009-11 and identified 59 725 CKD patients. Obesity was defined as a body mass index ≥25 kg/m2. MetS was defined as the presence of three or more metabolic risks. RESULTS: The cumulative event rate of cardiovascular (CV) events, progression to end-stage kidney disease (ESKD) and all-cause mortality was the lowest among obese patients without MetS (all P < .001). In multivariable analysis, obese (versus non-obese) patients without MetS were not at increased risks of CV events [adjusted hazard ratio (HR) 1.02 (95% confidence interval 0.94-1.11)] or progression to ESKD [0.92 (0.77-1.09)]. Their risk of all-cause mortality was significantly decreased [0.82 (0.75-0.90)]. These findings were consistently observed in overweight, obese and morbidly obese patients without MetS. Moreover, despite a linear increase in HR for each additional metabolic abnormality in both obese and non-obese patients, the slope of HR increase for CV events was significantly slower in obese patients (P for interaction = .038). CONCLUSIONS: Obesity without MetS did not increase the risk of CV complications or progression to ESKD. The healthy effect of obesity on all-cause mortality risk and its weakening effect on the association between metabolic hazards and CV risk should be considered in CKD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Kang SY, Lee YH, Jeong SJ, et al. How obesity and metabolic syndrome affect cardiovascular events, progression to kidney failure and all-cause mortality in chronic kidney disease. Nephrol Dial Transplant. 2024. PMID: 37791396. doi:10.1093/ndt/gfad214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。